[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544329":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":29,"responsibleParty":58,"collaborators":10,"id":60,"slug":10,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c",null,"Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.",[13],"Drug: Glecaprevir-pibrentasvir",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Glecaprevir-pibrentasvir","Glecaprevir-pibrentasvir 100 mg \u002F 40 mg 3 tab orally (PO) once daily for 56 days.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Tracey Bach, MBA","CONTACT","314-273-6075","habrockt@wustl.edu",{"name":27,"role":23,"phone":10,"phoneExt":10,"email":28},"Laura Marks, MD, PhD","marks@wustl.edu",[30,48],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Barnes Jewish Hospital","RECRUITING","St Louis","Missouri","63110","United States",{"type":38,"coordinates":39},"Point",[40,41],-90.19789,38.62727,{"lat":41,"lon":40},[44,46],{"name":45,"role":23,"phone":24,"phoneExt":10,"email":25},"Tracey Bach",{"name":27,"role":47,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":49,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":50,"geoPoint":52,"contacts":53},"Washington Univeristy",{"type":38,"coordinates":51},[40,41],{"lat":41,"lon":40},[54,56],{"name":55,"role":23,"phone":10,"phoneExt":10,"email":28},"Laura Marks, MD,PhD",{"name":57,"role":23,"phone":24,"phoneExt":10,"email":25},"Tracey Habrock-Bach, MBA",{"type":59,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100544329",false,"NCT06367465","Feasibility and Acceptability of HCV Treatment in Pregnancy","Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy","Inclusion Criteria:\n\n* Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.\n\nExclusion Criteria:\n\n\\-","FEMALE","18 Years",{"count":69,"type":70},50,"ESTIMATED","OBSERVATIONAL","Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use\n\nParticipant Duration: Approximately 1 year.\n\nAims:\n\nAim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs.\n\nAim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.",[74,75],"Hepatitis C","Pregnancy Complications","2026-06-05",{"date":78,"type":79},"2026-06-09","ACTUAL",{"date":81,"type":79},"2024-02-01",{"date":83,"type":70},"2026-12-28",{"name":5,"class":6},2]